Your browser doesn't support javascript.
loading
Difficulties on the access to innovative targeted therapies for lung cancer in Spain.
Calvo, Virginia; Camps, Carlos; Carcereny, Enric; Cobo, Manuel; Dómine, Manuel; García Campelo, María Rosario; González Larriba, José Luis; Guirado, María; Hernando-Trancho, Florentino; Massutí, Bartomeu; Nadal, Ernest; Rodríguez-Abreu, Delvys; Sánchez, Alfredo; Sullivan, Ivana Gabriela; Provencio, Mariano.
Afiliación
  • Calvo V; Oncology Department, Hospital Universitario Puerta de Hierro Majadahonda, Manuel de Falla 1, Majadahonda, 28222, Madrid, Spain. vircalvo@hotmail.com.
  • Camps C; Hospital General Universitario, Valencia, Spain.
  • Carcereny E; Institut Català d'Oncologia, Badalona, Spain.
  • Cobo M; Hospital Regional Universitario, Málaga, Spain.
  • Dómine M; Hospital Universitario Fundación Jiménez Díaz, IIS-FJD, Madrid, Spain.
  • García Campelo MR; Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.
  • González Larriba JL; Hospital Clínico San Carlos, Madrid, Spain.
  • Guirado M; Hospital General de Elche, Alicante, Spain.
  • Hernando-Trancho F; Hospital Clínico San Carlos, Madrid, Spain.
  • Massutí B; Hospital General Universitario Dr. Balmis, Alicante, Spain.
  • Nadal E; Institut Català d'Oncologia, l'Hospitalet de Llobregat, Barcelona, Spain.
  • Rodríguez-Abreu D; Hospital Universitario Insular de Gran Canaria, Las Palmas, Spain.
  • Sánchez A; Consorcio Hospital Provincial, Castellón, Spain.
  • Sullivan IG; Hospital Santa Creu i Sant Pau, Barcelona, Spain.
  • Provencio M; Oncology Department, Hospital Universitario Puerta de Hierro Majadahonda, Manuel de Falla 1, Majadahonda, 28222, Madrid, Spain.
Clin Transl Oncol ; 26(3): 597-612, 2024 Mar.
Article en En | MEDLINE | ID: mdl-37651020
PURPOSE: Spanish Lung Cancer Group (SLCG) conducted a review to analyze the barriers to access to innovative targeted therapies for non-small cell lung cancer (NSCLC) in clinical practice in Spain. METHODS: Review all relevant content published on websites of European Commission, European Medicines Agency, and Spanish Agency of Medicines and Medical Products regarding the authorization and access to oncology treatments. RESULTS: More than 20 targeted therapies are available to treat different molecular alterations in patients with NSCLC. European Commission has approved treatments for genomic alterations involving the following genes: ALK, RET, ROS1, EGFR, BRAF, NTRK, KRAS, MET. However, the availability of these therapies in Spain is not complete, as innovative treatments are not reimbursed or funded late, with only five of these alterations currently covered by National Health System. CONCLUSION: SLCG considers imperative to improve the access in Spain to innovative treatments for NSCLC to reduce inequity across European countries.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Clin Transl Oncol Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: Italia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Clin Transl Oncol Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: Italia